NZ585438A - Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide - Google Patents

Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Info

Publication number
NZ585438A
NZ585438A NZ585438A NZ58543808A NZ585438A NZ 585438 A NZ585438 A NZ 585438A NZ 585438 A NZ585438 A NZ 585438A NZ 58543808 A NZ58543808 A NZ 58543808A NZ 585438 A NZ585438 A NZ 585438A
Authority
NZ
New Zealand
Prior art keywords
methoxyphenoxy
benzenesulfonamide
hydroxyethoxy
pyrimidin
pyrimidinyl
Prior art date
Application number
NZ585438A
Other languages
English (en)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Prakash Bansode
Dattatraya Shinde
Sunanda Phadtare
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Priority to NZ600010A priority Critical patent/NZ600010A/xx
Publication of NZ585438A publication Critical patent/NZ585438A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ585438A 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide NZ585438A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (1)

Publication Number Publication Date
NZ585438A true NZ585438A (en) 2012-09-28

Family

ID=40262729

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Country Status (8)

Country Link
US (1) US8530488B2 (cg-RX-API-DMAC7.html)
EP (1) EP2222649A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011500780A (cg-RX-API-DMAC7.html)
CN (1) CN101939303B (cg-RX-API-DMAC7.html)
AU (1) AU2008315757A1 (cg-RX-API-DMAC7.html)
CA (1) CA2703230A1 (cg-RX-API-DMAC7.html)
NZ (2) NZ585438A (cg-RX-API-DMAC7.html)
WO (1) WO2009053748A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150547A2 (en) * 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
JP5535082B2 (ja) * 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
ES2650247T3 (es) 2008-02-08 2018-01-17 Generics [Uk] Limited Procedimiento de preparación del bosentán
EP2331513A1 (en) 2008-08-12 2011-06-15 Cadila Healthcare Limited Process for preparation of bosentan
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
EP1535613B1 (en) 1999-11-17 2010-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing a polymorphic form of atorvastatin calcium
AU779931B2 (en) 1999-12-16 2005-02-17 Teva Pharmaceutical Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
DK1254121T3 (da) * 2000-01-25 2006-06-12 Hoffmann La Roche Fremstilling af sulfonamider
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
WO2004076443A1 (en) 2003-02-25 2004-09-10 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
EP2150547A2 (en) 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
EP2072503B1 (en) * 2007-12-18 2011-10-26 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
ES2650247T3 (es) 2008-02-08 2018-01-17 Generics [Uk] Limited Procedimiento de preparación del bosentán
EP2268634A2 (en) 2008-03-13 2011-01-05 Actavis Group PTC EHF Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
US20100331352A1 (en) 2010-12-30
JP2011500780A (ja) 2011-01-06
CN101939303B (zh) 2014-06-11
CA2703230A1 (en) 2009-04-30
AU2008315757A1 (en) 2009-04-30
CN101939303A (zh) 2011-01-05
WO2009053748A2 (en) 2009-04-30
NZ600010A (en) 2013-11-29
EP2222649A2 (en) 2010-09-01
US8530488B2 (en) 2013-09-10
WO2009053748A3 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
NZ585438A (en) Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
PL1883397T3 (pl) Dyspergowalna tabletka bosertanu
Ludovici et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues
NZ624315A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
GEP20105073B (en) Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i
TW200508202A (en) Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
CL2013000372A1 (es) Compuestos derivados de 1-fenil(dihidropirimidina/pirimidina)-2,4(1h,3h)-diona; forma cristalina de n-(6-(3-tert-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il-metoxifenil)naftalen-2-il)metansulfonamida; proceso de preparacion;composicion farmaceutica; y su uso como antiviral para vhc (divisional cl 2794-08)
CN101914065A (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
HU0400405D0 (en) Novel compounds
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
WO2009080721A3 (en) 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
DK1578733T3 (da) Fremgangsmåde til fremstilling af rosuvastatin
MX2010007392A (es) Antagonistas de trpa1.
EP4275754A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
EP2982668A3 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
ZA201002214B (en) 3-methyl-2-((2s)-2-(4-(3-methyl-l,2,4-0xadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
ES2353271T3 (es) Procedimiento para la preparaciã“n de derivados asimã‰tricos de la 4,6-bis(ariloxi)pirimidina.
WO2006135839A3 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
UA106724C2 (uk) Спосіб отримання заміщених піримідинових похідних
NZ593117A (en) HPLC METHOD FOR THE ANALYSIS OF BOSENTAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS Chromatography mass spectrometry fragmentation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 OCT 2015 BY SPRUSON + FERGUSON

Effective date: 20130211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20151001

LAPS Patent lapsed